VenoStent
YC S20Houston, US · Founded 2017 · Delaware corporation · 17 employees · 10 known investors
Find your way into VenoStent
329 people in our graph share verified history with the VenoStent team — schools, employers, funds. One of them is your warm intro.
Tom Driscollunlockedknows Tim Boire · together at Vanderbilt University (overlapped)
×2knows the team · via Tufts University
×3knows the team · via Vanderbilt University
knows the team · via American Heart Association | American Stroke Association
knows the team · via St. Joseph's Prep
×2knows the team · via Vanderbilt University Owen Graduate School of Management
SelfWrap develops bioabsorbable wrap materials for vascular grafts that conform to individual patient anatomy and are designed to be absorbed by the body, unlike alloy-based alternatives. The company is developing the product for coronary and peripheral bypass grafting applications.
Founders & leadership· Y Combinator alumni (S20)
VenoStent was founded in 2017 by Tim Boire and Geoffrey Lucks.
TB
Tim BoireinCo-founder · President and CEOTim Boire holds a BS in Chemical & Biological Engineering and Biotechnology from Tufts University and a PhD in Biomedical Engineering from Vanderbilt University, where he developed smart polymeric biomaterials for vascular applications. He worked in R&D at Genzyme Corporation before founding VenoStent, which applies these materials to hemodialysis access.
GL
Geoffrey LucksinCOO and CofounderHe holds an MBA from Vanderbilt, a Master's degree in Bioethics from the University of Pennsylvania, and an undergraduate degree from the University of Wisconsin-Madison.
Board
JW
JM
Jim MonsorBoard director
RC
Investors · 10
Creative VenturesSan Francisco Bay Area · $1M
Good Growth CapitalCharleston
Health WildcattersDallas
Kube VC
Norwest Venture PartnersMenlo Park · $10M – $30M
Texas HALO FundHouston
TMC Venture FundHouston
Wealthing VC ClubPalo Alto
Y CombinatorSan Francisco · $500K
Good Life Sciences GenerationsreportedCharleston
Reported raises · per SEC filings
Form D private placements$29.2M disclosed across 6 rounds · 2018–2026
▶$10MraisedMay 2026 · 29 investors · Other Health CareRule 506(b)
▶$10MraisedMay 2026 · 29 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Geoffrey LucksExecutive Officer, Director
- Joel WhitleyDirector
- Timothy BoireExecutive Officer, Director
- Jim MonsorDirector
- Robert CrutchfieldDirector
- Offering amount
- $10M
- Amount sold
- $10M
- Minimum investment
- $10K
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.1MraisedJul 2023 · 60 investors · Other Health CareRule 506(b)
▶$16.1MraisedJul 2023 · 60 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Joel WhitleyDirector
- Timothy BoireExecutive Officer, Director
- Jim MonsorDirector
- Geoffrey LucksExecutive Officer, Director
- Robert CrutchfieldDirector
- Offering amount
- $21.2M
- Amount sold
- $16.1M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedFeb 2021 · 24 investors · Other Health CareRule 506(b)
▶$2.2MraisedFeb 2021 · 24 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Timothy BoireExecutive Officer, Director
- Kulika WeizmanDirector
- Geoffrey LucksExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $2.2M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$515KraisedJun 2020 · 16 investors · Other Health CareRule 506(b)
▶$515KraisedJun 2020 · 16 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Geoffrey LucksExecutive Officer, Director
- Timothy BoireExecutive Officer, Director
- Offering amount
- $535K
- Amount sold
- $515K
- First sale
- May 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$263.9KraisedJul 2019 · 8 investors · Other Health CareRule 506(b)
▶$263.9KraisedJul 2019 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Geoffrey LucksExecutive Officer, Director
- Timothy BoireExecutive Officer, Director
- Offering amount
- $300K
- Amount sold
- $263.9K
- Minimum investment
- $10K
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$70KraisedMar 2018 · 4 investors · Other Health CareRule 506(b)
▶$70KraisedMar 2018 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Geoffrey LucksExecutive Officer, Director
- Timothy BoireExecutive Officer, Director
- Offering amount
- $400K
- Amount sold
- $70K
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlap
Venova Medical9 shared keywordsVenova Medical develops the Velocity percutaneous arteriovenous fistula system, a minimally invasive medical device designed to create vascular access for hemodialysis patients more efficiently than traditional surgical methods. The system addresses barriers to AVF creation and maturation, targeting patients with chronic kidney disease who require dialysis access.
Boston Scientific9 shared keywordsBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
Vantis Vascular8 shared keywordsVantis Vascular develops vascular intervention technology, including the CrossFast integrated vascular delivery system with an auto-locking inner monorail microcatheter and outer delivery catheter for complex PCI procedures. Founded by physicians, the company is also developing next-generation intravascular lithotripsy (IVL) and peripheral below-the-knee (BTK) solutions for vascular interventionalists.</parameter>
<parameter name="founders">[{"full_name": "Jason Turner", "title": "Chief Executive Officer"}, {"full_name": "Tim Fischell", "title": "Chief Medical Officer"}, {"full_name": "Frank Saltiel", "title": "Chief Clinical Officer"}, {"full_name": "Gary McCord", "title": "Chief Commercial Officer"}, {"full_name": "Mike Mirizzi", "title": "Chief Technology Officer"}, {"full_name": "Marc Monahan", "title": "Chief Financial Officer"}]</parameter>
<parameter name="hq_city">San Jose
Intervene Inc8 shared keywordsInterVene, Inc. is a medical device company that has developed a fully integrated mechanical thrombectomy system to treat venous in-stent restenosis and residual thrombotic venous obstructions and occlusions. Its technology targets venous disease conditions such as postthrombotic syndrome that current therapies fail to address.
Innova Vascular7 shared keywordsInnova Vascular is a medical device company focused on the vascular space, led by a founder with a background in developing and commercializing vascular medical devices. The page provides limited detail about the company's specific products.
AngioDynamics7 shared keywordsAngioDynamics develops and manufactures medical devices aimed at treating serious diseases and improving patient outcomes. Founded in 1988, the company serves healthcare professionals and operates globally across North America, Europe, the Middle East, and South America.
Vesalio6 shared keywordsVesalio develops stroke treatment technology, specifically devices and systems for endovascular neurosurgical interventions to treat acute ischemic and hemorrhagic stroke. The company serves hospitals and neurosurgeons seeking advanced treatment options.
Companies competing with VenoStent for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2020 | $299.9K |
| National Science Foundation | Phase II | 2019 | $744.2K |
| National Science Foundation | Phase ISTTR | 2018 | $224.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does VenoStent do?
- SelfWrap develops bioabsorbable wrap materials for vascular grafts that conform to individual patient anatomy and are designed to be absorbed by the body, unlike alloy-based alternatives. The company is developing the product for coronary and peripheral bypass grafting applications.
- Who founded VenoStent?
- VenoStent was founded by Tim Boire, Geoffrey Lucks in 2017.
- Who are VenoStent's investors?
- VenoStent's investors include Creative Ventures, Good Growth Capital, Health Wildcatters, Kube VC, Norwest Venture Partners, Texas HALO Fund, TMC Venture Fund, Wealthing VC Club and 2 more.
- How much funding has VenoStent raised?
- VenoStent has disclosed $29.2M raised across 6 rounds.
- Where is VenoStent headquartered?
- VenoStent is headquartered in Houston, US.